SNCA and Parkinson disease: Modified rotenone PD models using a low dose and chronic administration have shown promising outcomes with selective nigrostriatal neurodegeneration and positive aggregation of α-synuclein cytoplasmic inclusions (Betarbet et al., 2000; Sherer et al., 2003; Zhu et al., 2004; Inden et al., 2011).